Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 44

Results For "science"

2145 News Found

RPG Life Sciences reports Rs. 6.92 crore PAT in Q4 FY2020-21
News | May 03, 2021

RPG Life Sciences reports Rs. 6.92 crore PAT in Q4 FY2020-21

The company reported total income of Rs.390.05 crores during the 12 months period ended March 31, 2021


Glenmark Life Sciences files for IPO
News | April 18, 2021

Glenmark Life Sciences files for IPO

The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals


Zeon Corporation to acquire Ushio’s microfluidics biz
News | December 27, 2025

Zeon Corporation to acquire Ushio’s microfluidics biz

Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology


Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA
Drug Approval | December 26, 2025

Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA

These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products


Asahi Kasei Pharma to move R&D hub to Shonan iPark in 2027
News | December 24, 2025

Asahi Kasei Pharma to move R&D hub to Shonan iPark in 2027

Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia


Ipsen acquires Simcere Zaiming’s innovative ADC SIM0613
Biopharma | December 24, 2025

Ipsen acquires Simcere Zaiming’s innovative ADC SIM0613

The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.


Gilead licenses Assembly Bio's investigational Herpes drugs after positive phase 1b data
Clinical Trials | December 24, 2025

Gilead licenses Assembly Bio's investigational Herpes drugs after positive phase 1b data

Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option


Neurocrine’s Valbenazine fails to show benefit in largest dyskinetic cerebral palsy trial
Clinical Trials | December 24, 2025

Neurocrine’s Valbenazine fails to show benefit in largest dyskinetic cerebral palsy trial

Adverse events were consistent with valbenazine’s established safety profile


SRM Global Hospitals performs Tamil Nadu’s first TactiFlex radiofrequency ablation to save 80-yr-old patient
Hospitals | December 23, 2025

SRM Global Hospitals performs Tamil Nadu’s first TactiFlex radiofrequency ablation to save 80-yr-old patient

TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.